Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population-based observational study.
Crohn’s disease
Epidemiology
biologics
inflammatory bowel diseases
surgery
Journal
Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
6
5
2022
Statut:
ppublish
Résumé
Heterogeneity in the treatment of a disease is a marker of suboptimal quality of care. The aim of this study is to evaluate the heterogeneity in the treatment used and the outcomes for Crohn's disease (CD) in Catalonia. All patients with CD included in the Catalan Health Surveillance System (data on more than seven million individuals from 2011 to 2017) were identified. The different Catalonian health areas were grouped into 19 district groups (DG). Treatments used rates (systemic corticosteroids, non-biological and biological immunosuppressant) and outcomes rates (hospitalization and surgery) were calculated. The use of systemic corticosteroids presented a decreasing trend over the study period, with an average rate of use in the different territories between 11% and 17%. The use of non-biological immunosuppressant treatment has remained stable, with an average rate of use ranging from 22% to 40% per year depending on the DG. The use of biological immunosuppressant treatment increased with an average rate of use in the different territories ranging from 10 to 23%.Hospitalizations for any reason showed an increasing trend between 2011 and 2017 with an average rate of between 23% and 32% per year depending on the area. Hospitalizations for CD presented a decreasing trend, with an average rate of between 5% and 11% per year. Surgical treatment remained stable over time, rates per year were between 0.5% and 2%. A remarkable geographical heterogeneity in the use of different treatments and in outcomes of CD was observed between different geographical areas of Catalonia. KEY MESSAGEThere is a notable geographical heterogeneity in the administration of biological and immunosuppressive treatments to Crohn's disease patients in Catalonia.There is also a geographical heterogeneity in their rates of hospitalization and surgical intervention.
Sections du résumé
BACKGROUND
Heterogeneity in the treatment of a disease is a marker of suboptimal quality of care. The aim of this study is to evaluate the heterogeneity in the treatment used and the outcomes for Crohn's disease (CD) in Catalonia.
METHODS
All patients with CD included in the Catalan Health Surveillance System (data on more than seven million individuals from 2011 to 2017) were identified. The different Catalonian health areas were grouped into 19 district groups (DG). Treatments used rates (systemic corticosteroids, non-biological and biological immunosuppressant) and outcomes rates (hospitalization and surgery) were calculated.
RESULTS
The use of systemic corticosteroids presented a decreasing trend over the study period, with an average rate of use in the different territories between 11% and 17%. The use of non-biological immunosuppressant treatment has remained stable, with an average rate of use ranging from 22% to 40% per year depending on the DG. The use of biological immunosuppressant treatment increased with an average rate of use in the different territories ranging from 10 to 23%.Hospitalizations for any reason showed an increasing trend between 2011 and 2017 with an average rate of between 23% and 32% per year depending on the area. Hospitalizations for CD presented a decreasing trend, with an average rate of between 5% and 11% per year. Surgical treatment remained stable over time, rates per year were between 0.5% and 2%.
CONCLUSION
A remarkable geographical heterogeneity in the use of different treatments and in outcomes of CD was observed between different geographical areas of Catalonia. KEY MESSAGEThere is a notable geographical heterogeneity in the administration of biological and immunosuppressive treatments to Crohn's disease patients in Catalonia.There is also a geographical heterogeneity in their rates of hospitalization and surgical intervention.
Identifiants
pubmed: 35499519
doi: 10.1080/07853890.2022.2069851
pmc: PMC9126589
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1255-1264Références
Gac Sanit. 2019 Jan - Feb;33(1):24-31
pubmed: 29129491
BMJ Qual Improv Rep. 2016 Jul 29;5(1):
pubmed: 27559471
Healthc Q. 2019 Jul;22(2):6-9
pubmed: 31556371
Scand J Gastroenterol. 2018 Aug;53(8):952-957
pubmed: 30205699
Aliment Pharmacol Ther. 2007 Oct 1;26(7):1005-18
pubmed: 17877507
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Gastroenterol Hepatol (N Y). 2006 Jul;2(7):486-488
pubmed: 28289350
Clin Gastroenterol Hepatol. 2015 Jun;13(6):1197-200
pubmed: 25460565
J Clin Med. 2020 Sep 08;9(9):
pubmed: 32911630
World J Gastroenterol. 2018 Jun 14;24(22):2363-2372
pubmed: 29904243
Inflamm Bowel Dis. 2019 Jun 18;25(7):1208-1217
pubmed: 30601983
United European Gastroenterol J. 2021 Sep;9(7):766-772
pubmed: 34089303
N Engl J Med. 2016 Nov 17;375(20):1946-1960
pubmed: 27959607
Lancet Gastroenterol Hepatol. 2019 Apr;4(4):287-295
pubmed: 30765267
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
J Crohns Colitis. 2017 Feb;11(2):135-149
pubmed: 27660342
World J Gastroenterol. 2021 Jan 14;27(2):208-223
pubmed: 33510560
Gastroenterology. 2014 Jan;146(1):96-109.e1
pubmed: 23770005
J Crohns Colitis. 2013 Dec;7(11):878-89
pubmed: 23018106
Inflamm Bowel Dis. 2011 Jan;17(1):450-7
pubmed: 20602466
J Gastroenterol Hepatol. 2019 Jul;34(7):1166-1174
pubmed: 30672608
Aliment Pharmacol Ther. 2017 Jan;45(1):3-13
pubmed: 27862107
Clin Gastroenterol Hepatol. 2009 Feb;7(2):168-74, 174.e1
pubmed: 18952199
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Gut. 2019 Nov;68(11):1953-1960
pubmed: 31300515
N Engl J Med. 2009 Nov 19;361(21):2066-78
pubmed: 19923578
Gastroenterology. 2013 Nov;145(5):996-1006
pubmed: 23896172
PLoS Med. 2014 Aug 26;11(8):e1001711
pubmed: 25158064
Aliment Pharmacol Ther. 2018 Feb;47(3):364-370
pubmed: 29164650
J Crohns Colitis. 2017 Dec 4;11(12):1512
pubmed: 29088340
Lancet. 2002 May 4;359(9317):1541-9
pubmed: 12047962
Biomed Res Int. 2013;2013:581631
pubmed: 23484133
Gastroenterology. 2019 Apr;156(5):1345-1353.e4
pubmed: 30639677
J Crohns Colitis. 2019 Sep 19;13(9):1163-1172
pubmed: 30766997
Dig Liver Dis. 2016 Nov;48(11):1302-1307
pubmed: 27481587
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2031-2045.e11
pubmed: 33127595
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66
pubmed: 33033392
Ann Med. 2018 Nov;50(7):613-619
pubmed: 30247071